Investment Analysts’ Weekly Ratings Updates for Precigen (PGEN)

Several analysts have recently updated their ratings and price targets for Precigen (NASDAQ: PGEN):

• 8/8/2026 – Precigen was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 8/5/2026 – Precigen had its price target raised by HC Wainwright from $14.00 to $18.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Precigen was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/3/2026 – Precigen had its “buy” rating reaffirmed by HC Wainwright. They now have a $14.00 price target on the stock.
• 7/17/2026 – Precigen had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other news, CFO Harry Jr. Thomasian sold 100,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $6.06, for a total transaction of $606,000.00. Following the sale, the chief financial officer directly owned 254,535 shares in the company, valued at $1,542,482.10. This trade represents a 28.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Rutul R. Shah sold 32,739 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $6.86, for a total transaction of $224,589.54. Following the transaction, the chief operating officer owned 465,012 shares of the company’s stock, valued at $3,189,982.32. This represents a 6.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 989,239 shares of company stock worth $5,472,960. 41.40% of the stock is currently owned by company insiders.

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.